Standard biopsies sometimes fail to detect prostate cancer or produce false positives. MRI plus MRI-guided biopsies not only produce more accurate results but carry a fair price tag, researchers said.
The expanded approval makes enzalutamide the first and only approved androgen receptor signaling inhibitor in the nonmetastatic castration-sensitive prostate cancer setting.
Oligoarticular PsA can significantly affect quality of life even though few joints are affected, and there s a lack of relevant clinical data to guide treatment.